- Home
- INGN vs ACIU Comparison
INGN vs ACIU Comparison
Compare INGN & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INGN
- ACIU
- Stock Information
- Founded
- INGN 2001
- ACIU 2003
- Country
- INGN United States
- ACIU Switzerland
- Employees
- INGN N/A
- ACIU N/A
- Industry
- INGN Industrial Specialties
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- INGN Health Care
- ACIU Health Care
- Exchange
- INGN Nasdaq
- ACIU Nasdaq
- Market Cap
- INGN 219.3M
- ACIU 213.3M
- IPO Year
- INGN 2014
- ACIU 2016
- Fundamental
- Price
- INGN $8.69
- ACIU $3.53
- Analyst Decision
- INGN Strong Buy
- ACIU Strong Buy
- Analyst Count
- INGN 3
- ACIU 2
- Target Price
- INGN $11.00
- ACIU $10.00
- AVG Volume (30 Days)
- INGN 185.5K
- ACIU 262.9K
- Earning Date
- INGN 11-06-2025
- ACIU 11-04-2025
- Dividend Yield
- INGN N/A
- ACIU N/A
- EPS Growth
- INGN N/A
- ACIU N/A
- EPS
- INGN N/A
- ACIU N/A
- Revenue
- INGN $343,472,000.00
- ACIU $36,362,036.00
- Revenue This Year
- INGN $7.93
- ACIU N/A
- Revenue Next Year
- INGN $8.18
- ACIU $1,022.98
- P/E Ratio
- INGN N/A
- ACIU N/A
- Revenue Growth
- INGN 5.15
- ACIU 86.71
- 52 Week Low
- INGN $5.70
- ACIU $1.43
- 52 Week High
- INGN $12.91
- ACIU $3.99
- Technical
- Relative Strength Index (RSI)
- INGN 58.20
- ACIU 68.67
- Support Level
- INGN $8.24
- ACIU $2.70
- Resistance Level
- INGN $8.84
- ACIU $3.99
- Average True Range (ATR)
- INGN 0.32
- ACIU 0.29
- MACD
- INGN -0.03
- ACIU 0.09
- Stochastic Oscillator
- INGN 61.49
- ACIU 80.31
About INGN Inogen Inc
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.